Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.
Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data...
Những tác giả chính: | Griffiths, R, Gleeson, M, Mikhael, J, Danese, MD |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
2012
|
Những quyển sách tương tự
-
Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma
Bằng: Griffiths, R, et al.
Được phát hành: (2012) -
Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
Bằng: Griffiths, R, et al.
Được phát hành: (2012) -
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.
Bằng: Griffiths, R, et al.
Được phát hành: (2011) -
Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
Bằng: Griffiths, R, et al.
Được phát hành: (2012) -
Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
Bằng: Griffiths, R, et al.
Được phát hành: (2010)